Aligning Artificial Intelligence and Laboratory Execution in Drug Discovery
From In Silico Design to In Vitro Impact
Yann Gaston-Mathé, Iktos
Artificial intelligence is transforming molecular design, but synthesis remains the limiting step in drug discovery. To translate computational advances into real productivity gains, organizations must better align digital design with laboratory execution. AI-driven orchestration provides a practical framework to coordinate design, synthesis, and testing within existing R&D infrastructures, accelerating the transition from in silico hypotheses to in vitro validation and improving the productivity of the DMTA cycle.
The Acceleration Paradox
Artificial intelligence is reshaping how molecules are conceived. Generative models can now explore vast regions of chemical space, proposing and optimizing candidate structures with unprecedented speed.
Read more with free registration
Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.
most read
Lead or Lag: Europe’s AI Materials Race
How AI and Robotics are reshaping the race for materials discovery.
US Tariffs Fatal for European Pharma
Trump's tariff policy is a considerable burden and a break with previous practice.
ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance
The ECA Foundation, one of the most important not-for-profit organizations for regulatory expertise in the pharmaceutical industry, aims to become the largest independent GMP/GDP organization in the world.
ISPE Good Practice Guide: Validation 4.0
The Validation 4.0 Guide provides a comprehensive approach to ensuring product quality and patient safety throughout a pharmaceutical product's lifecycle.
Pharma 4.0 – the Key Enabler for Successful Digital Transformation in Pharma
Part 1: Building a Business Case for Pharma 4.0